Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

@article{Bauss2016CharacterizationOA,
  title={Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.},
  author={F E - Roche Bauss and Martin Lechmann and Ben-Fillippo Krippendorff and Roland F. Staack and Frank Herting and Matthias Festag and Sabine Imhof-Jung and Friederike Hesse and Marc Pompiati and Gwendlyn Kollmorgen and Rita da Silva Mateus Seidl and Birgit Bossenmaier and Wilma Lau and Christian Schantz and Jan Olaf Stracke and Ulrich Brinkmann and Masanori Onda and Ira Pastan and Klaus Bosslet and G. Niederfellner},
  journal={Molecular oncology},
  year={2016},
  volume={10 8},
  pages={1317-29}
}
Mesothelin overexpression in lung adenocarcinomas correlates with the presence of activating KRAS mutations and poor prognosis. Hence SS1P, a mesothelin-targeted immunotoxin, could offer valuable treatment options for these patients, but its use in solid tumor therapy is hampered by high immunogenicity and non-specific toxicity. To overcome both obstacles we developed RG7787, a de-immunized cytotoxic fusion protein comprising a humanized SS1 Fab fragment and a truncated, B-cell epitope silenced… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…